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1 Abstract
Background: Many studies and meta-analyses have investigated the effects of statins on cancer incidence but
without showing consistent effects.
Methods: A series of nested case-control studies was conducted covering 574 UK general practices within the
QResearch database. Cases were patients with primary cancers diagnosed between 1998 and 2008. The
associations between statin use and risk of ten site-specific cancers were estimated with conditional logistic
regression adjusted for co-morbidities, smoking status, socio-economic status, and use of non-steroidal anti-
inflammatory drugs, cyclo-oxygenase-2 inhibitors and aspirin.
Results: 88125 cases and 362254 matched controls were analysed. The adjusted odds ratio for any statin use and
cancer at any site were 1.01 (95%CI 0.99 to 1.04). For haematological malignancies there was a significant reduced
risk associated with any statin use (odds ratio 0.78, 95%CI 0.71 to 0.86). Prolonged (more than 4 years) use of
statins was associated with a significantly increased risk of colorectal cancer (odds ratio 1.23, 95%CI 1.10 to 1.38),
bladder cancer (odds ratio 1.29, 95%CI 1.08 to 1.54) and lung cancer (odds ratio 1.18, 95%CI 1.05 to 1.34). There
were no significant associations with any other cancers.
Conclusion: In this large population-based case-control study, prolonged use of statins was not associated with an
increased risk of cancer at any of the most common sites except for colorectal cancer, bladder cancer and lung
cancer, while there was a reduced risk of haematological malignancies.
2 Background
Multiple randomised controlled trials have demon-
strated the benefits of statins in improving survival for
patients with ischaemic heart disease [1-5] and this has
caused a substantial increase in statin use. While there
are definite benefits from statins in reduction of mortal-
ity in high risk patients, uncertainties remain about
whether statins might increase or decrease the risk of
cancer[6-8]. This is important because statins are pre-
scribed for extended periods to large numbers of
patients.
The effect of long-term statin use is quite complex
because the multiple properties of statins go beyond
lipid lowering. There is evidence that statins increase
endothelial dysfunction [9] and lower inflammatory
m a r k e r s [ 1 0 ]b u ti ti ss t i l ln o tc l e a rw h e t h e rt h e ym a y
affect the risk of cancer. Experimental data (primarily
using rats) have shown both carcinogenicity of statins
[11] and no effect on carcinogenesis[12]. Some studies
performed on human cancer cells in vitro have sug-
gested that statins may be chemo-prophylactic against
various types of cancer including colon[13] and breast
cancer[14,15]. It has also been found that statins may
suppress the growth of cancer cells in vitro by causing
the cells to pause in the G1 phase of the mitotic cycle
[16] and by increasing cell death[17].
There have been many randomised controlled trials of
statins, but cancer has never been a primary outcome.
The numbers of cancer cases have been relatively small
and the duration of the trials too short to detect the
effect of statins on cancer risk. The results from 35 ran-
domised control trials have been summarised in a meta-
analysis[18] reporting no association between statin use
and overall cancer risk. However, the latest published
results of another randomised controlled trial, not
included in the meta-analysis, on the use of a combina-
tion of simvastatin and ezetimibe in patients with aortic
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(105 vs.70, P = 0.01)[19].
A number of observational studies were designed to
assess risk of particular cancers in statin users and the
results have been aggregated in a meta-analysis[7]. How-
ever, only some of the studies reported statin use of
more than 5 years[20]. None of those findings were sta-
tistically significant except for one study reporting a
decreased risk of prostate cancer, but based only on 42
statin users[21]. A recent study of statin use and ten
common cancers[22] found a significantly reduced risk
of haematological malignancies and an increased risk of
endometrial cancer associated with more than 5 years of
statin use.
All studies were smaller than the proposed one, and
they were too dissimilar in their definitions of statin use
to be analysed together: they either studied different
types of statin or statin types were not specified. They
also had differing lengths of intervention or follow-up,
and included different confounding factors in their
analyses.
Given the uncertainty regarding risk of cancer in asso-
ciation with statin usage, we designed a study to deter-
mine the risk for the most common incident cancers
associated with taking statins including for prolonged
periods using a very large population-based research
d a t a b a s eQ R E S E A R C H .T h es i z eo ft h es t u d yh a s
enabled us to adjust for use of other drugs and many
potential confounding factors.
3 Methods
3.1 Study design, data source and population
We conducted a series of nested case control studies
within a cohort of patients registered with practices in the
UK contributing to the QRESEARCH database (version
20). The QResearch database (http://www.qresearch.org)
is one of the largest general practice databases containing
anonymised clinical records for over 11 million patients
registered with 574 UK general practices. The information
recorded on the database includes patient demographics
(year of birth, sex, socio-demographic data derived from
UK census 2001), characteristics (height, weight, smoking
status), clinical diagnoses, symptoms, and prescribed med-
ications including repeat prescriptions. The database has
been validated by comparing birth rates, death rates, con-
sultation rates, prevalence and mortality rates with other
data sources, including the General Household Survey and
the General Practice Research Database, and has demon-
strated good levels of completeness and consistency
[23,24]. Practices were included in the analysis only if they
had complete data transmission until at least 1
st July 2008.
We identified an open cohort of patients registered
with the study practices during the 10 year study period
between 1st Jan 1998 and 1st July 2008. We then used
READ codes to select all cases aged between 30 and 100
years with a first record of any cancer in the patients’
electronic records occurring during the study period.
Each case was linked to 5 controls alive and registered
with the practice at the time of diagnosis of the case
and matched by age, sex, practice and calendar time.
Controls were allocated an index date which was the
date on which their matched case was first diagnosed
with cancer.
3.2 Exclusions
Cases with secondary cancers (READ codes: B56, B57,
B58) were excluded. Cases and controls with a diagnosis
of any cancer before the index date were excluded. In
addition, for breast cancer, we excluded cases and con-
trols with any prior record of mastectomy or prescrip-
tions for tamoxifen since they could be breast cancer
cases without a recorded diagnosis in their record. To
ensure completeness of exposure data we also excluded
temporary residents and patients with fewer than 6
years of medical records before the index date for the
main analysis - and fewer than 10 years for the further
analysis.
3.3 Primary outcomes
We determined the risks for the most common cancers
in the UK[25], comparing these for patients prescribed
statins against those not prescribed the drugs. The
investigated cancers and corresponding READ codes
were: Breast cancer (women, B34), Prostate cancer
(men, B46), Lung cancer (B22), Bladder cancer (B49),
Haematological malignancies (B6), Gastric cancer (B11),
Oesophageal cancer (B10), Colorectal cancer (B13, B14),
Pancreatic cancer (B17) and Melanoma (B32). As hae-
matological malignancies cover a range of diseases, pos-
sibly differentially affected by statins, we also
investigated leukaemia (B63-B6z), lymphoma (B60-B62)
and myeloma (B63) separately.
3.4 Exposure variables
Statin exposure was determined based on all prescrip-
tions for statins until 1 year before the index date (date
of diagnosis or equivalent date for controls). The drugs
included were atorvastatin, pravastatin, fluvastatin, ceri-
vastatin, rosuvastatin, and simvastatin. Prescriptions in
the year before the index date were ignored because
including these could lead to results being affected by
reverse causality - prescribing in cases in this period
might be the result of consultations relating to early
cancer symptoms before the recorded diagnosis and this
could attenuate any protective effect or exaggerate any
harmful effect.
For the main analysis, we considered a 60-month per-
iod comprising statin prescriptions for the 13 to 72
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Page 2 of 12months prior to the index date. For the additional analy-
sis, covering a follow-up of 10 years, the period consid-
ered was 98 months - for the 13 to 120 months prior to
the index date.
Statin use was categorised in a number of ways. We
considered a patient as a statin user if they had at least 2
prescriptions in the 60-month period (or the 98-month
period for the 10-year analysis). We estimated the cumu-
lative use of statins by extracting the duration of use for
every prescription and, for groups of prescriptions with
inter-prescription gaps of less than 60 days, we calculated
overall course times from the start of the first prescrip-
tion to the end of the last prescription. We then calcu-
lated cumulative use as the sum of all overall course
times and for the main analysis categorized cumulative
use for each patient as: no use; less than 12 months; 13
to 24 months; 25 to 36 months; 37 to 48 months; 49 to
60 months. A test for trend was performed using the
actual number of months of use. For the further analysis,
covering a follow-up period of 10 years, the categorisa-
t i o no ft h et i m ep e r i o df o rs t a t i nu s ew a s :n ou s e ;l e s s
than 12 months, 13 to 24 months, 25 to 48 months, 49 to
72 months, and more than 73 months.
If there were at least 2 prescriptions in the 60-month
main study period (or in the 98-month additional study
period), we conducted analyses for the following indivi-
dual statin types: simvastatin, atorvastatin, cerivastatin,
fluvastatin, pravastatin and rosuvastatin. For the most
common types - simvastatin, atorvastatin and pravasta-
tin - we also examined the effect of cumulative use on
cancer risk.
Statin dosage was calculated as median dose across
the observation time period, and was categorised as low,
medium or high according to statin efficacy[26]. The
effect of stopping statin usage on risk of cancer was
investigated in the main study only by comparing the
last prescription date in the study period with the date
one year before the index date and categorising as: no
statin use in the 13 to 72 months prior to the index
date; still on statins; stopped statins 13 to 24 months
before the index date; and stopped statins 25 or more
months prior to the index date.
3.5 Potential confounding variables
We adjusted for variables which are established cancer
risk factors: diabetes[27], rheumatoid arthritis[28],
hypertension[29] and body mass index (< 25, 25-29.99,
≥ 30 kg/m
2)[30], if recorded at least 1 year before the
index date, and for smoking status (non-smoker, ex-
smoker, current smoker) and individual Townsend
deprivation score (measure of socio-economic status, in
fifths), if recorded before the index date. The Townsend
score was based on 2001 postcode-related census data,
with higher scores indicating greater level of material
deprivation and was used because there is a link
between deprivation and incidence of some types of
cancer[31]. We adjusted for cardiovascular disease as
the main reason for statin therapy. For breast cancer we
also accounted for any previous benign breast disease
(fibrocystic disease, intraductal papilloma, fibroadenoma)
and for family history of breast cancer. For colorectal
cancer, additional confounders considered were colitis
and Crohn’s disease.
We also adjusted for use of traditional non steroidal
anti-inflammatory drugs, cyclooxygenase-2 inhibitors
and aspirin, as several studies have found protective
effects for non-steroidal anti-inflammatory drugs and
aspirin on various types of cancer[32,33], in particular
on colorectal cancer[33]. We categorised the number of
prescriptions for these drugs in the 60-month main
study period as: none; 1 to 12; 13 to 24; and 25 or more
(adding 25 to 48 and 49 or more for the 98-month addi-
tional study period); and adjusted for those categories in
assessing cancer risk. We also included in the analyses
use of other medications likely to increase the risk of
cancer (hormone replacement therapy and oral contra-
ceptive use for breast cancer analysis[34]) if there were
at least 2 prescriptions of a drug in the 60-month main
study period or 98-month additional study period.
3.6 Statistical analysis
We used conditional logistic regression to estimate odds
ratios with 95% confidence intervals for cancer overall
and each of the specific cancer sites. As body mass
index, smoking status and Townsend deprivation score
may be important confounders and have a certain
amount of missing data, we used multiple imputation
for the missing values[35,36]. We used the ICE proce-
dure in STATA to obtain 5 imputed datasets and
applied Rubin’s rules to combine effect estimates and
estimate standard errors to allow for uncertainty caused
by the missing data. We repeated the imputation proce-
dure for each type of cancer separately.
The initial analysis model determined the unadjusted
odds ratios for each cancer associated with statin pre-
scriptions according to: any use of statins in the 60-
month study period (at least 2 prescriptions in the 13 to
72 months before the index date); cumulative duration
of use; and the median prescribed dose. A multivariate
model determined the odds ratio for each cancer asso-
ciated with statin prescriptions adjusted for the potential
confounding effects of variables listed above. For com-
parison with the analyses using imputed data for smok-
ing status and body mass index, we also ran complete
case analyses including only cases and controls with
complete data as well as analyses using indicator vari-
ables for missing categories of smoking, deprivation and
body mass index.
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base so did not do a pre-study sample size calculation.
According to post-hoc calculation, in order to detect an
odds ratio of 0.8 (or 1.2) with 80% power at 1% signifi-
cance for an exposure that occurs in 15% of controls a
s a m p l eo f2 6 8 5c a s e s( o r3 4 2 4c a s e s )w o u l db en e e d e d .
We checked that we had sufficient power for analysis of
the six commoner cancers. STATA v 10 was used for all
the analyses. We used a 1% significance level to account
for the multiple outcomes.
4 Results
Overall there were 118,780 patients with a recorded
diagnosis of cancer at any site within the study period.
3,810 patients had diagnoses of secondary cancers so
were removed from the analysis. Thirty six patients
were coded with cancers applicable only to the other
gender and were also removed. For breast cancer 370
cases and 302 controls with a previous history of mas-
tectomy were excluded as were a further 685 cases and
471 controls with a previous history of tamoxifen use.
This left a total of 113,879 patients with a first diagnosis
of cancer during the study period and 568,958 controls.
After removing patients with less than 6 years of medi-
cal records there were 88,125 cases of primary cancer
matched with 362,254 controls. Eighty-one percent of
cases and 71% of controls also had complete data for 10
years of follow-up. The proportions of cases with differ-
ent types of cancer were similar to proportions in can-
cer registration statistics in England for 2003[37] for
patients older than 30 years.
4.1 Baseline characteristics
Table 1 shows baseline characteristics for cases of can-
cer at any site and their matched controls. Fifty-three
percent of the cases were men; the median age at diag-
nosis was 69 years (interquartile range: 60 to 77).
Seventy six percent of cases and 73% of controls had
complete data for body mass index, smoking status and
Townsend deprivation score.
Cases and controls had similar patterns of co-morbid-
ity except for diabetes (8.1% in cases vs. 7.4% in con-
trols). The difference in proportion of diabetic patients
was most marked in pancreatic cancer cases (12.7% vs.
8.3% in controls).
4.2 Statin exposure
Overall 15.5% of cases and 15.1% of controls had at least
2 statin prescriptions between 13 to 72 months prior to
the index date. Most of the statin users (95% of cases
a n dc o n t r o l s )h a ds t a t i np r e scriptions for more than a
year. Median numbers of scripts for statin users were 19
(interquartile ranges, 9 to 32) for cases and for controls.
Median numbers of months on statin were 28 for cases
and controls (interquartile ranges, 12 to 50 for cases
and 12 to 49 for controls).
The most frequently prescribed statins were simvasta-
tin (9.2% of cases and 9.0% of controls), atorvastatin
(6.1% of cases and 5.9% of controls) and pravastatin
(1.6% of cases and controls). The other statins were pre-
scribed to less than 1% of the population. Very few ator-
vastatin users had low dose prescriptions (3 cases and
28 controls) and few pravastatin users had high dose
prescriptions (4 cases and 12 controls). Simvastatin
dosage was distributed evenly. Long-term statin use was
associated with higher dose: in patients prescribed sta-
tins for more than 4 years, 42% of cases and 43% con-
trols were on high doses compared with 31% cases and
31% controls on high doses in patients prescribed statins
for less than 4 years.
The results of the main analyses, based on patients
with at least 6 years of medical records, are shown in
Tables 2, 3, 4 and Figure 1. Table 5 shows the odds
ratios for each cancer according to cumulative duration
of statin use in patients with at least 10 years of medical
records.
4.2.1 Cancer of any site
The analysis for overall risk of cancer (at any site) did
not show a significant association with any statin use
(Table 2). Patients with a cumulative prescription dura-
tion of more than one year had a similar risk of cancer
of any site compared with patients with no statin pre-
scriptions (adjusted odds ratio (AOR) 1.02, 95%CI 0.99
to 1.05). Analyses of trends for duration of use (Table 3)
and dosage, as well as analysis of use of individual sta-
tins (Table 4), did not show any effect of statins on
overall risk of cancer.
4.2.2 Colorectal cancer
There was no overall increase of colorectal cancer risk
in statin users (AOR 1.07, 95%CI 1.00 to 1.15, P =
0.056), with a slight association for patients with pre-
scriptions for more than a year (AOR = 1.09, 95%CI
1.01 to 1.18, P = 0.036), which was not however statisti-
cally significant at P < 0.01. Further analysis showed a
significant association with duration of use of statins
(Ptrend= 0.001), with a 23% increased risk for 49 to 60
months of use of (AOR 1.23, 95%CI 1.10 to 1.38) com-
pared with no use. The analysis of the median pre-
scribed dose of statins revealed a significant association
with an 18% increased risk on high dose of statin (AOR
1.18, 95%CI 1.07 to 1.31, P = 0.001).
Analyses of individual statins showed an association
between colorectal cancer and atorvastatin (Ptrend=
0.001), with an increased risk of colorectal cancer asso-
ciated with atorvastatin use of 4 or more years (AOR
1.51, 95%CI 1.24 to 1.83).
The risk of colorectal cancer was not significantly
increased for patients who stopped taking statins more
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medical records
Cases (N = 88125) Controls (N = 362254)
Sex
female 41749 (47.4) 170173 (47.0)
male 46376 (52.6) 192081 (53.0)
Age band (years)
30-54 13151 (14.9) 49906 (13.8)
55-64 19638 (22.3) 80107 (22.1)
65-74 26758 (30.4) 111698 (30.8)
75-84 25013 (28.4) 106278 (29.3)
85 + 3565 (4.0) 14265 (3.9)
Deprivation
Townsend quintile 1, most affluent 22072 (25.0) 92287 (25.5)
Townsend quintile 2 18998 (21.6) 79067 (21.8)
Townsend quintile 3 17338 (19.7) 71358 (19.7)
Townsend quintile 4 15325 (17.4) 61767 (17.1)
Townsend quintile 5, most deprived 11896 (13.5) 45971 (12.7)
Townsend missing 2496 (2.8) 11804 (3.3)
Body mass index (kg/m
2)
15-24 26721 (30.3) 105883 (29.2)
25-29 27285 (31.0) 108803 (30.0)
30-49 12922 (14.7) 51413 (14.2)
not recorded 21197 (24.1) 96155 (26.5)
Smoking status
non-smoker 54307 (61.6) 233135 (64.4)
ex-smoker 7567 (8.6) 23842 (6.6)
current smoker 17275 (19.6) 54869 (15.1)
not recorded 8976 (10.2) 50408 (13.9)
Co-morbidities
Cardiovascular disease 14278 (16.2) 58123 (16.0)
Diabetes 7115 (8.1) 26802 (7.4)
Hypertension 27104 (30.8) 109797 (30.3)
Osteoarthritis 12807 (14.5) 52586 (14.5)
Rheumatoid arthritis 1310 (1.5) 5132 (1.4)
Colitis
1 124 (1.1) 293 (0.6)
Crohn’s disease
1 28 (0.2) 109 (0.2)
Benign breast disease
2 1094 (7.0) 2937 (4.7)
Family history of breast cancer
2 539 (3.4) 1249 (2.0)
Medications (in previous 13-72 months)
NSAID 35697 (40.5) 140642 (38.8)
COX2 inhibitors 6901 (7.8) 26974 (7.4)
Aspirin 19895 (22.6) 79067 (21.8)
Hormone replace therapy
2 3289 (21.0) 10973 (17.4)
Oral contraceptive pill
2 523 (3.3) 1638 (2.6)
1) Based only on cases with colorectal cancer and their controls
2) Based only on female cases with breast cancer and their controls
Vinogradova et al. BMC Cancer 2011, 11:409
http://www.biomedcentral.com/1471-2407/11/409
Page 5 of 12than 2 years before the index date (AOR 1.03, 95%CI
0.81 to 1.31).
The increased risk of colorectal cancer associated with
longer duration of statin use found in patients with at
least 6 years of medical records was not supported by
the trend test of months on medication in patients with
at least 10 years of medical records (p = 0.069).
4.2.3 Bladder cancer
For bladder cancer, there was a borderline 15%
increased risk of cancer associated with any use of
statins (P = 0.012) and a 16% increased risk associated
with more than one year’s use (P = 0.018), but these
were not statistically significant. For patients with
more than 48 months of statin use, risk of bladder
cancer was 29% higher (AOR, 1.29, 95% 1.08 to 1.54, P
= 0.006) but the trend test for duration was not statis-
tically significant (Ptrend = 0.014). No particular type of
statin was significantly associated with an increased
risk. The risk of bladder cancer was not significantly
increased in patients who stopped taking statins more
Table 2 Use of statins in cases and controls in 13 to 72 months prior the index date by cancer site (in cases and
matched controls with at least 6 years of medical records)
Cancer Total number
of cases
Total number
of controls
N of statin users
in cases (%)
N of statin users in
controls (%)
Unadjusted OR (95%
CI)
Adjusted
# OR (95%
CI)
P-
value
breast† 15666 62938 1481 (9.5) 6227 (9.9) 0.98 (0.92 to 1.04) 1.00 (0.93 to 1.08) 0.993
prostate 14764 61853 2774 (18.8) 11508 (18.6) 1.03 (0.98 to 1.08) 1.08 (1.01 to 1.14) 0.016
colorectal‡ 11749 48624 2000 (17.0) 7770 (16.0) 1.12 (1.06 to 1.19) 1.07 (1.00 to 1.15) 0.056
lung 10163 42415 1998 (19.7) 7621 (18.0) 1.16 (1.09 to 1.23) 1.07 (0.99 to 1.16) 0.095
blood 7185 29162 973 (13.5) 4339 (14.9) 0.91 (0.84 to 0.99) 0.78 (0.71 to 0.86) < 0.001
bladder 4227 17559 856 (20.3) 3125 (17.8) 1.23 (1.12 to 1.34) 1.15 (1.03 to 1.29) 0.012
skin 3249 13115 433 (13.3) 1675 (12.8) 1.12 (0.99 to 1.26) 1.08 (0.93 to 1.26) 0.292
oesophagus 3159 13041 496 (15.7) 2106 (16.1) 0.97 (0.87 to 1.09) 0.88 (0.77 to 1.01) 0.072
pancreas 2110 8762 365 (17.3) 1397 (15.9) 1.15 (1.01 to 1.32) 0.96 (0.82 to 1.14) 0.671
stomach 1992 8279 322 (16.2) 1363 (16.5) 1.00 (0.87 to 1.16) 0.86 (0.72 to 1.02) 0.078
All cancers 88125 362254 13621 (15.5) 54606 (15.1) 1.07 (1.05 to 1.09) 1.01 (0.99 to 1.04) 0.280
# Adjusted for Townsend quintile, body mass index, smoking status, myocardial infarction, coronary heart disease, diabetes, hypertension, stroke, rheumatoid
arthritis, use of NSAIDs, Cox2-inhibitors, aspirin
† Also adjusted for family history of breast cancer, use of oral contraceptives, hormone-replace therapy
‡ Also adjusted for colitis and Crohn’s disease
Table 3 Cumulative duration of statin use in cases and controls in 13 to 72 months prior to the index date by cancer
site (in cases and matched controls with at least 6 years of medical records)
Less than 12 months 13 to 24 months 25 to 48 months 49 months and more
cancer Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
P-*
value
breast† 433/1811 1.01 (0.90 to 1.13) 289/1292 0.93 (0.81 to 1.07) 430/1685 1.07 (0.95 to 1.21) 329/1439 0.95 (0.83 to 1.09) 0.719
prostate 668/2784 1.05 (0.95 to 1.15) 560/2187 1.14 (1.03 to 1.26) 796/3295 1.09 (0.99 to 1.19) 750/3242 1.05 (0.95 to 1.16) 0.084
colorectal‡ 525/2038 1.05 (0.95 to 1.17) 400/1595 1.04 (0.92 to 1.17) 539/2230 1.02 (0.92 to 1.14) 536/1907 1.23 (1.10 to 1.38) 0.002
lung 485/1857 1.02 (0.90 to 1.15) 406/1478 1.11 (0.97 to 1.27) 549/2233 1.01 (0.90 to 1.14) 558/2053 1.18 (1.05 to 1.34) 0.013
blood 255/1082 0.84 (0.72 to 0.98) 201/860 0.81 (0.68 to 0.96) 277/1307 0.73 (0.63 to 0.84) 240/1090 0.76 (0.65 to 0.89) <
0.001
bladder 209/785 1.13 (0.95 to 1.34) 174/611 1.18 (0.98 to 1.42) 240/952 1.06 (0.90 to 1.25) 233/777 1.29 (1.08 to 1.54) 0.014
skin 120/422 1.19 (0.95 to 1.49) 61/347 0.74 (0.55 to 0.99) 141/474 1.23 (0.99 to 1.54) 111/432 1.08 (0.84 to 1.39) 0.373
oesophagus 126/571 0.82 (0.67 to 1.02) 97/394 0.91 (0.71 to 1.17) 128/601 0.82 (0.66 to 1.02) 145/540 1.04 (0.83 to 1.30) 0.705
pancreas 87/367 0.85 (0.66 to 1.10) 73/269 1.02 (0.76 to 1.36) 113/390 1.09 (0.86 to 1.40) 92/371 0.97 (0.74 to 1.28) 0.521
stomach 76/317 0.87 (0.66 to 1.15) 69/271 0.90 (0.67 to 1.20) 94/404 0.86 (0.67 to 1.11) 83/371 0.85 (0.64 to 1.12) 0.167
All cancers 3467/
13935
1.01 (0.97 to 1.05) 2752/
10855
1.02 (0.98 to
1.07)
3868/
15708
1.00 (0.96 to
1.04)
3534/
14108
1.04 (1.00 to
1.09)
0.057
# Adjusted for Townsend quintile, body mass index, smoking status, myocardial infarction, coronary heart disease, diabetes, hypertension, stroke, rheumatoid
arthritis, use of NSAIDs, Cox2-inhibitors, aspirin
† Also adjusted for family history of breast cancer, benign breast disease, use of oral contraceptives, hormone-replace therapy
‡ Also adjusted for colitis and Crohn’s disease
* Trend test based on number of months prescribed
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controls with at least 6 years of medical records)
Atorvastatin Pravastatin Simvastatin
cancer Cases/
Controls
Adjusted Odds ratio
(95%CI)
#
P-
value
Cases/
Controls
Adjusted Odds ratio
(95%CI)
#
P-
value
Cases/
Controls
Adjusted Odds ratio
(95%CI)
#
P-
value
breast† 596/2574 0.96 (0.86 to 1.06) 0.387 152/630 1.02 (0.85 to 1.23) 0.835 871/3720 0.98 (0.89 to 1.07) 0.584
prostate 1023/4398 0.99 (0.91 to 1.07) 0.781 314/1182 1.15 (1.00 to 1.31) 0.046 1668/6924 1.05 (0.99 to 1.13) 0.117
colorectal‡ 826/2934 1.17 (1.07 to 1.28) 0.001 212/786 1.09 (0.93 to 1.28) 0.289 1152/4783 0.96 (0.88 to 1.04) 0.273
lung 786/2912 1.07 (0.97 to 1.18) 0.179 195/837 0.93 (0.78 to 1.11) 0.435 1205/4588 1.06 (0.97 to 1.15) 0.202
blood 381/1653 0.87 (0.77 to 0.99) 0.041 95/452 0.84 (0.66 to 1.06) 0.138 579/2592 0.82 (0.73 to 0.91) <
0.001
bladder 353/1212 1.19 (1.03 to 1.37) 0.015 87/309 1.08 (0.84 to 1.40) 0.544 513/1893 1.10 (0.97 to 1.25) 0.119
skin 168/655 1.03 (0.84 to 1.25) 0.805 43/178 0.91 (0.64 to 1.30) 0.609 259/998 1.06 (0.90 to 1.26) 0.483
oesophagus 197/846 0.88 (0.73 to 1.05) 0.159 62/226 1.05 (0.78 to 1.42) 0.740 298/1222 0.94 (0.80 to 1.09) 0.403
pancreas 143/557 0.92 (0.74 to 1.14) 0.439 37/152 0.92 (0.62 to 1.35) 0.667 224/852 0.99 (0.83 to 1.20) 0.952
stomach 123/500 0.94 (0.75 to 1.18) 0.604 41/149 1.03 (0.71 to 1.50) 0.880 186/819 0.85 (0.70 to 1.03) 0.106
All cancers 5357/
21253
1.01 (0.98 to 1.05) 0.461 1442/
5680
1.02 (0.96 to 1.09) 0.488 8102/
32769
1.00 (0.97 to 1.03) 0.844
# Adjusted for Townsend quintile, body mass index, smoking status, myocardial infarction, coronary heart disease, diabetes, hypertension, stroke, rheumatoid
arthritis, use of NSAIDs, Cox2-inhibitors, aspirin
† Also adjusted for family history of breast cancer, benign breast disease, use of oral contraceptives, hormone-replace therapy
‡ Also adjusted for colitis and Crohn’s disease
Figure 1 Risk of cancer in patients using statins for more than 365 days in 13 to 72 months prior to the index date.
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Page 7 of 12Table 5 Cumulative duration of statin use in cases and controls in 13 to 120 months prior to the index date by cancer site in cases and controls with 10 or
more years of recorded data
Less than 12 months 13 to 24 months 25 to 48 months 49 to 72 months 73 months and more
cancer Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
Cases/
Controls
Adjusted Odds
ratio (95%CI)
#
P-*
value
breast† 363/1338 1 (0.86 to 1.16) 254/962 0.96 (0.81 to 1.15) 346/1208 1.06 (0.90 to 1.25) 169/634 0.93 (0.75 to 1.15) 131/542 0.85 (0.67 to 1.08) 0.220
prostate 545/2119 0.99 (0.87 to 1.12) 489/1609 1.19 (1.04 to 1.36) 641/2424 1.06 (0.94 to 1.19) 369/1394 1.07 (0.93 to 1.24) 320/1234 1.12 (0.96 to 1.32) 0.173
colorectal‡ 446/1527 1.06 (0.92 to 1.23) 327/1224 1.03 (0.88 to 1.21) 429/1625 0.97 (0.84 to 1.13) 285/902 1.20 (1.01 to 1.43) 213/711 1.21 (0.99 to 1.48) 0.069
lung 419/1375 1.06 (0.91 to 1.25) 342/1064 1.21 (1.01 to 1.43) 458/1586 1.05 (0.89 to 1.23) 259/950 1.00 (0.82 to 1.21) 235/734 1.17 (0.95 to 1.45) 0.240
blood 202/821 0.72 (0.59 to 0.88) 160/616 0.8 (0.64 to 1.00) 233/966 0.74 (0.61 to 0.89) 133/468 0.87 (0.68 to 1.11) 90/428 0.55 (0.41 to 0.73) <
0.001
bladder 172/565 1.14 (0.91 to 1.43) 137/456 1.19 (0.93 to 1.53) 190/681 1.01 (0.81 to 1.26) 117/360 1.19 (0.91 to 1.57) 94/280 1.37 (1.02 to 1.86) 0.062
skin 110/312 1.41 (1.04 to 1.89) 56/270 0.79 (0.55 to 1.13) 112/349 1.21 (0.89 to 1.64) 50/176 0.87 (0.56 to 1.36) 56/185 1.04 (0.70 to 1.55) 0.626
oesophagus 103/409 0.9 (0.67 to 1.20) 75/272 1.01 (0.72 to 1.42) 105/445 0.81 (0.61 to 1.09) 68/248 1.09 (0.77 to 1.55) 59/185 1.03 (0.70 to 1.52) 0.870
pancreas 76/277 0.89 (0.63 to 1.24) 61/196 1.22 (0.84 to 1.78) 86/286 0.99 (0.71 to 1.38) 50/172 1.04 (0.69 to 1.56) 40/148 0.85 (0.53 to 1.37) 0.475
stomach 58/232 0.84 (0.58 to 1.22) 60/206 0.82 (0.56 to 1.19) 77/301 0.86 (0.61 to 1.21) 35/150 0.56 (0.35 to 0.90) 38/165 0.63 (0.39 to 1.00) 0.008
All cancers 2890/
10413
0.99 (0.94 to 1.05) 2303/
8005
1.05 (0.99 to 1.11) 3107/
11437
0.98 (0.93 to 1.03) 1776/
6319
1.01 (0.95 to 1.08) 1462/
5259
1.02 (0.95 to 1.10) 0.958
# Adjusted for Townsend quintile, body mass index, smoking status, myocardial infarction, coronary heart disease, diabetes, hypertension, stroke, rheumatoid arthritis, use of NSAIDs, Cox2-inhibitors, aspirin
† Also adjusted for family history of breast cancer, benign breast disease, use of oral contraceptives, hormone-replace therapy
‡ Also adjusted for colitis and Crohn’s disease
* Trend test based on number of months prescribed
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2than 2 years before the index date (AOR 0.94, 95%CI
0.62 to 1.40).
The additional analysis restricted to patients with at
least 10 years of medical records showed similar results,
but these were not statistically significant.
4.2.4 Lung cancer
Although the unadjusted risk of lung cancer appeared to
be significantly higher in statin users (unadjusted odds
ratio (UOR) 1.16, 95%CI 1.09 to 1.23, P < 0.001), after
adjusting for cardiovascular disease the association
became much weaker (OR 1.07, 95%CI 1.00 to 1.14, P =
0.067) and did not noticeably change after further
adjusting for other factors.
The unadjusted trend test for months of statin use was
significant (P < 0.001) and use of statins for more than 4
years was associated with an increased risk of cancer
(UOR 1.22, 95%CI 1.10 to 1.35, P < 0.001). After adjusting
for cardiovascular disease and other factors, these associa-
tions were also reduced but long-term usage remained sig-
nificant (AOR 1.18, 95%CI 1.05 to 1.34, P = 0.007).
Analyses repeated on patients with 10 years of medical
records did not show any statistically significant effect of
statins for either overall or long term use.
4.2.5 Prostate cancer
Although the analysis demonstrated an 8% increased
risk of prostate cancer for overall statin user and a 9%
increased risk for patients with prescriptions covering
more than a year, these associations were not statisti-
cally significant (P = 0.016 and P = 0.011). There were
no dose or duration relationships in patients with either
6 years or 10 years of medical records.
4.2.6 Haematological malignancies
There was a 22% reduced blood cancer risk for overall
statin use (AOR 0.78, 95%CI 0.71 to 0.86, P < 0.001)
and a 24% reduction for patients with statin prescrip-
tions of more than a year (AOR 0.76, 95%CI 0.68 to
0.85), with a significant trend for duration of use (Ptrend
< .001). No differential effects were found for particular
types of statin. Patients who stopped taking statins for
more than 2 years had the same risk of cancer as non-
statin users (AOR 0.90, 95%CI 0.67 to 1.23).
Although lymphoma, myeloma and leukaemia were
similarly associated with overall use of statins and use
for more an year, only leukaemia had associations with
duration and dose with significant trend tests (Ptrend =
0.002 and Ptrend < 0.001), a 26% risk reduction (AOR
0.74, 95%CI 0.62 to 0.87, P = 0.001) with at least two
years of statin prescriptions, and a 25% risk reduction
on high dose (AOR 0.75, 95%CI 0.61 to 0.92, P = 0.006).
4.2.7 Other cancers
There were no significant associations with statin use
for any other cancers.
4.2.8 Sensitivity analyses
The sensitivity analyses treating missing values for
smoking, and body mass index as separate categories
produced very similar results. The complete case ana-
lyses resulted in very similar odds ratios, but the confi-
dence intervals were wider due to the reduced number
of observations (results available from the authors).
5 Discussion
In this large population-based case control study to
determine the risk of common cancers associated with
use of statins, we confirmed that use of statins does not
affect the overall risk of cancer. We did find some evi-
dence of an increased risk of colorectal cancer in
patients using statins for 4 or more years or with a high
statin dose. We also found an increased risk of bladder
cancer and lung cancer in patients prescribed statins for
4 or more years. Conversely, we found a reduced risk of
haematological malignancies in statin users.
There are a large number of studies devoted to statins
and cancer risk summarised in meta-analyses[6-8] which
did not show an adverse or protective effect of statins
on the overall incidence of cancer. However, the cate-
gorisation of ‘any cancer’ is not a specific enough end-
point of study as it covers a range of diseases, each with
a different aetiology and course of development.
Colorectal cancer, as one of the most common can-
cers, has been studied extensively but only eight epide-
miological studies looked at the effect of long-term
statin use (at least 4 years). Four of them[38-41] had
odds ratios greater than unity (from 1.00 to 1.15) and
four of them[22,42-44] reported odds ratios less than
unity (from 0.71 to 0.83), but none of these findings
reached statistically significant levels even at the 5%
level. The effect of dose in our study might, however, be
a replication of the effect of cumulative use because a
high dose was more likely to be prescribed for patients
who had been on statins for substantial period of time.
The other two most common cancers, breast and
prostate, also account for a number of studies but there
has been no definite outcome in associating any of these
with use of statins and our null results are consistent
with this. Studies for prostate cancer have been aggre-
gated into a meta-analysis [45], which did not find any
significant association with overall risk of prostate can-
cer and another meta-analysis[46] looking at breast can-
cer studies also failed to demonstrate a protective or
adverse effect of statins.
For bladder cancer, results of a meta-analysis consid-
ering 5 studies showed an increased, but not significant,
association between stain use and cancer risk[7]. There
have been very few studies investigating the long-term
Vinogradova et al. BMC Cancer 2011, 11:409
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Page 9 of 12effect of statin use on bladder cancer. One study[39]
showed an increased risk for more than 5 years of statin
use, which is consistent with our findings, but another
very recent one found no significant association for cur-
rent use of statins for more than 5 years [22]. Both stu-
dies, however, were much smaller.
Our findings of a significant increase in unadjusted
lung cancer risk for statin use and for long-term use
were both significantly decreased by adjusting for cardi-
ovascular disease, but after adjusting for all factors,
long-term use still showed a significant association with
increased lung cancer risk. There is no causal link
between cardiovascular disease and lung cancer but
there is a strong association of both conditions with
smoking. The finding about possible increased risk from
long-term use is consistent with the results of two other
studies[22,39], although their findings were not
significant.
The decreased risk of haematological malignancies
could be explained by reverse causality, as patients with
such diagnoses are more likely to have lower lipid levels
[47] although we did restrict our statin exposure to pre-
scriptions at least 12 months before diagnosis. The
effect of statins on leukaemia has been studied in vitro
and there is evidence that statins might suppress the
growth of promyelocitic[48] and lymphocytic[49] leuke-
mic cells. However, no epidemiological studies have pro-
vided significant evidence of any statin effect on
incidence of leukaemia.
Our study has several strengths. It is substantially lar-
ger and has greater statistical power than any previous
study. This has allowed us to perform the analyses sepa-
rately for different cancers within the same population.
We had a substantial number of patients with at least
10 years of records, which also allowed us to examine
long-term statin use. The study is based on computer-
recorded prescribing and morbidity data collected pro-
spectively. The study was not subject to response bias
or recall bias as the exposure data were recorded before
t h ed a t eo fd i a g n o s i so rp s eudo-diagnosis. Any bias
from misclassification is likely to be small because the
level of accuracy and completeness of medical records
in general practices has been shown to be high [50].
Matching the controls on sex, age, practice and calen-
dar year removed confounding by these factors. Any
bias from misclassification of statin use is likely to be
minimal as more than 99% of all general practitioners’
repeat prescriptions are recorded on computer[51]. We
minimised the possibility of misleading data from the
effects of undiagnosed cancer in new medical records by
excluding prescriptions, diagnoses of co-morbidities and
records of body mass index made within the 12 months
prior to the date of the diagnosis or pseudo-diagnosis of
cancer.
Our study has some limitations. Information on cer-
tain risk factors for cancer, such as level of physical
activity, alcohol use, and diet, and information on can-
cer screening tests (mammography, prostate-specific
antigen test and colonoscopy) were not reliably
recorded on the database and not included in the analy-
sis so there may be some residual confounding.
Although we adjusted the risk of cancer for possible
e f f e c t so fs m o k i n g ,o b e s i t y ,d e p r i v a t i o n ,c o - m o r b i d i t i e s
and the use of other medications, residual confounding
may also result from misclassification of those variables.
Values of body mass index or smoking status, were
missing for about 22% of cases and 25% of controls, so
we substituted missing values using multiple imputa-
tion. We did not include blood test results in the analy-
sis, in particular high-density lipoproteins and total-
serum cholesterol, because they were not consistently
recorded on the data base and would be more likely to
be recorded in statin users.
Although our data contain detailed information on
drug prescriptions, this may not reflect actual use. How-
ever there is no reason to think that any non-adherence
would systematically differ between cases and controls.
Another possible source of misclassification arises
from a statin (simvastatin 10 mg) having become avail-
able over the counter in May 2004 in the UK, which
would affect mostly younger people who are not entitled
to free prescriptions[52] and only a small part of the
study period. However, among statin users 81.4% of
cases and 82.4% of controls were aged 65 years or older
and therefore entitled to free prescribed medications.
Analyses repeated on this group of patients obtained
similar results, which suggests that any misclassification
of use of medication because of over-the-counter pur-
chase is not an explanation for our findings.
6 Conclusion
In summary, we have conducted a large population-
based case-control study that examined the effect of sta-
tins on the risk of cancer and found that there is no
effect from prolonged use of statins on overall risk of
cancer, but that prolonged use of statins may be asso-
ciated with an increased risk of colorectal cancer, blad-
der cancer and lung cancer and a decreased risk of
haematological malignancies.
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